Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Popp, Felix C, Fillenberg, Barbara, Eggenhofer, Elke, Renner, Philipp, Dillmann, Johannes, Benseler, Volker, Schnitzbauer, Andreas A, Hutchinson, James, Deans, Robert, Ladenheim, Deborah, Graveen, Cheryl A, Zeman, Florian, Koller, Michael, Hoogduijn, Martin J, Geissler, Edward K, Schlitt, Hans J, Dahlke, Marc H
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2011
Soggetti:
Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166276/
https://ncbi.nlm.nih.gov/pubmed/21798013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-124
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi